Table 4.

Clinical outcomes with targeted therapy in metastatic triple-negative breast cancer

Ref.	Line of treatment	Regimen	No.	ORR (%)	CBR (%)	PFS (mo)	OS (mo)
O’Shaughnessy et al[40]	First line	Gemcitabine +	61	52	56	5.9	12
		Carboplatin ±	62	32	34	3.6	7.7
		Inipari2
Isakoff et al[42]	First line	Veliparib2 + TMZO	41	37.5	62.5	5.5	NR
Carey et al[44]	First line	Cetuxim12 ±	71	18	31	22	12
		Carboplatin1	54	6	10
O’Shaughnessy et al[45]	First or second line	Irinotecan +	52	49	NR	5.1	15.5
		Carboplatin ±
		Cetuxim12	51	30		4.7	12.3
Finn et al[49]	First line	Dasatini2	44	4.6	9.2	8.3 wk	NR
Baselga et al[46]	First or second line	Cisplatin ±	115	20	NR	3.73	12.9
		Cetuxim12	58	10		1.5	9.4
Gray et al[50]	First line	Paclitaxel ±	122	48	NR	11.83	NR
(E2100)		Bevacizum12	111	22		5.9
Miles et al[51]	First line	Docetaxel ±	58	64	NR	103	NR
(AVADO)		Bevacizum12	53	46		8
Robert et al[52]	First line	Tax/Anthr1	96	NR	NR	6.5	NR
(RiBBON-1)		± Bevacizum12	46			6.2
		Cap ±	87	NR	NR	6.13	NR
		Bevacizum12	50			4.2
Brufsky et al[53]	Second line	Cap, tax, gem/vinorel, ±	112	413	NR	6.03	17.9
(RiBBON-2)		Bevacizum12	47	18		2.7	12.6

¹Cross over to cetuximab + carboplatin arm after progressive disease;

²For entire cohort;

³Significant. TMZO: Temozolamide; ORR: Overall response rate; CBR: Clinical benefit rate; PFS: Progression free survival; NR: Not reported; Tax: Taxanes; Cap: Capecitabine; Gem: gemcitabine.